Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G.

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

2.

Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.

Choi HY, Yong CS, Yoo BK.

Ann Pharmacother. 2010 Jan;44(1):117-26. doi: 10.1345/aph.1M380. Epub 2009 Dec 15. Review.

PMID:
20009003
3.

Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.

Wagstaff AJ.

Drugs. 2009;69(3):319-26. doi: 10.2165/00003495-200969030-00007. Review.

PMID:
19275275
4.

Plerixafor: a peripheral blood stem cell mobilizer.

Kessans MR, Gatesman ML, Kockler DR.

Pharmacotherapy. 2010 May;30(5):485-92. doi: 10.1592/phco.30.5.485. Review.

PMID:
20411999
5.
6.

Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.

Uy GL, Rettig MP, Cashen AF.

Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . Review.

PMID:
18847313
7.

[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].

Hansen PB, Gaarsdal E.

Ugeskr Laeger. 2009 Nov 2;171(45):3272-5. Review. Danish.

PMID:
19887056
8.

Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells.

Cashen AF.

Drugs Today (Barc). 2009 Jul;45(7):497-505. doi: 10.1358/dot.2009.45.7.1395292. Review.

PMID:
19834627
9.

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.

Hartmann T, Hübel K, Monsef I, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2015 Oct 20;(10):CD010615. doi: 10.1002/14651858.CD010615.pub2. Review.

PMID:
26484982
10.

Optimizing stem cell collection through CXCR4 antagonists.

Mahaseth H, Kaufman J.

Front Biosci (Schol Ed). 2012 Jan 1;4:611-9. Review.

PMID:
22202080
11.

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Keating GM.

Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. Review.

PMID:
21861545
12.

Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.

Jantunen E, Lemoli RM.

Transfusion. 2012 Apr;52(4):906-14. doi: 10.1111/j.1537-2995.2011.03349.x. Epub 2011 Oct 7. Review.

PMID:
21981351
13.

A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.

Lerro KA, Medoff E, Wu Y, Seropian SE, Snyder E, Krause D, Cooper DL.

Bone Marrow Transplant. 2003 Dec;32(12):1113-7. Review.

PMID:
14647264
14.

The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).

De Clercq E.

Biochem Pharmacol. 2009 Jun 1;77(11):1655-64. doi: 10.1016/j.bcp.2008.12.014. Epub 2008 Dec 31. Review.

PMID:
19161986
15.

Mobilization of hematopoietic stem cells into the peripheral blood.

Damon LE, Damon LE.

Expert Rev Hematol. 2009 Dec;2(6):717-33. doi: 10.1586/ehm.09.54. Review.

PMID:
21082960
16.

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.

De Clercq E.

Pharmacol Ther. 2010 Dec;128(3):509-18. doi: 10.1016/j.pharmthera.2010.08.009. Epub 2010 Sep 15. Review.

PMID:
20826182
17.

Peripheral blood stem cell mobilization tactics.

Rosenbeck LL, Srivastava S, Kiel PJ.

Ann Pharmacother. 2010 Jan;44(1):107-16. doi: 10.1345/aph.1M289. Epub 2009 Dec 8. Review.

PMID:
19996324
18.

[Collection of hematopoietic progenitor cells from healthy donors].

Bojanić I, Cepulić BG, Mazić S.

Acta Med Croatica. 2009 Jun;63(3):237-44. Review. Croatian.

PMID:
19827352
19.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG..

Leukemia. 2009 Oct;23(10):1904-12. doi: 10.1038/leu.2009.127. Epub 2009 Jun 25.

PMID:
19554029
20.

Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.

Pusic I, DiPersio JF.

Curr Opin Hematol. 2010 Jul;17(4):319-26. doi: 10.1097/MOH.0b013e328338b7d5. Review.

PMID:
20473162

Supplemental Content

Support Center